Samantha is an Investment Analyst at Angelini Ventures, having joined as a Fellow: a role in which she supported the investment team while contributing to the establishment of the Singapore office and the launch of EspressoLab. Prior to joining Angelini Ventures, she started as a scientist at the Experimental Drug Development Centre (EDDC) where she worked on NK cell engagers for oncology and I&I applications, a project that is now part of a collaboration with Daiichi Sankyo. She then transitioned to the EDDC Business Development and Alliance Management team where she oversaw licensing and strategic partnering of the large molecule portfolio, including a clinical-stage ADC programme that ran in Singapore and US.

Prior to EDDC, Samantha worked as a life sciences consultant at Princeton Biopartners, producing evidence-based strategic recommendations supporting the uptake of innovative technologies across disease areas including oncology, neurology and infectious disease. She was also a co-founding managing director of Nucleate Singapore, an associate chapter of the global non-profit, Nucleate, that launched out of the Harvard Biotechnology Club to connect early career researchers to the local and global biotech space. Sam holds a PhD from Harvard University in translational medicine, and a BSc in Biomedical Science from Imperial College London, both supported by the A*STAR National Science Scholarship.